Choreo LLC Grows Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Choreo LLC lifted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 58.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,954 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,087 shares during the quarter. Choreo LLC’s holdings in Jazz Pharmaceuticals were worth $363,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. GAMMA Investing LLC grew its stake in shares of Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 121 shares in the last quarter. UMB Bank n.a. boosted its holdings in Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 129 shares during the period. Ellsworth Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 0.4% in the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock worth $4,675,000 after acquiring an additional 149 shares during the last quarter. Exchange Traded Concepts LLC increased its position in Jazz Pharmaceuticals by 2.2% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,045 shares of the specialty pharmaceutical company’s stock worth $868,000 after buying an additional 155 shares during the period. Finally, Cooper Financial Group boosted its stake in Jazz Pharmaceuticals by 3.7% during the 4th quarter. Cooper Financial Group now owns 4,334 shares of the specialty pharmaceutical company’s stock valued at $534,000 after purchasing an additional 156 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $135.44 on Thursday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company has a market capitalization of $8.19 billion, a PE ratio of 19.08, a price-to-earnings-growth ratio of 0.92 and a beta of 0.56. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $136.55. The business has a 50 day simple moving average of $122.97 and a 200 day simple moving average of $116.89.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the transaction, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 5,053 shares of company stock worth $617,442 in the last 90 days. 4.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Robert W. Baird boosted their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. TD Cowen decreased their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. HC Wainwright restated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $177.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.